Published in Ann Clin Microbiol Antimicrob on May 18, 2006
Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev (2014) 1.21
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med (2003) 15.48
Active bacterial core surveillance of the emerging infections program network. Emerg Infect Dis (2001) 2.65
Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei. FEMS Microbiol Lett (2000) 2.57
Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis (2003) 2.00
Invasive pneumococcal disease in Dallas County, Texas: results from population-based surveillance in 1995. Clin Infect Dis (1998) 1.58
Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother (2005) 1.43
The genus Hafnia: from soup to nuts. Clin Microbiol Rev (2006) 1.40
Clinical significance of extraintestinal Hafnia alvei isolates from 61 patients and review of the literature. Clin Infect Dis (1996) 1.21
Bacteriologic and epidemiologic characteristics of Enterobacter hafniae and Enterobacter liquefaciens. J Infect Dis (1971) 1.21
Population-based epidemiology of intensive care: critical importance of ascertainment of residency status. Crit Care (2004) 1.14
Heterogeneity of AmpC cephalosporinases of Hafnia alvei clinical isolates expressing inducible or constitutive ceftazidime resistance phenotypes. Antimicrob Agents Chemother (2000) 1.13
Natural antimicrobial susceptibility patterns and biochemical identification of Escherichia albertii and Hafnia alvei strains. Diagn Microbiol Infect Dis (2005) 1.07
Extraintestinal infection due to Hafnia alvei. Eur J Clin Microbiol Infect Dis (2000) 0.96
Clinical characteristics of nosocomial and community-acquired extraintestinal infections caused by Hafnia alvei. Scand J Infect Dis (2005) 0.88
Community-acquired Hafnia alvei infection. Clin Infect Dis (1997) 0.84
Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents (2010) 3.77
A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin Infect Dis (2009) 3.17
Occurrence and outcome of fever in critically ill adults. Crit Care Med (2008) 2.90
Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol (2005) 2.89
New quadriplex PCR assay for detection of methicillin and mupirocin resistance and simultaneous discrimination of Staphylococcus aureus from coagulase-negative staphylococci. J Clin Microbiol (2004) 2.64
Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis (2009) 2.63
Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates. Antimicrob Agents Chemother (2007) 2.48
Severe bloodstream infections: a population-based assessment. Crit Care Med (2004) 2.39
The role of international travel in the worldwide spread of multiresistant Enterobacteriaceae. J Antimicrob Chemother (2012) 2.33
Laboratory detection of Enterobacteriaceae that produce carbapenemases. J Clin Microbiol (2012) 2.24
Staphylococcus aureus bloodstream infections: risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis (2008) 2.21
Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci U S A (2014) 2.20
Community-onset extended-spectrum beta-lactamase (ESBL) producing Escherichia coli: importance of international travel. J Infect (2008) 2.11
Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis (2003) 2.00
Population-based laboratory surveillance for Escherichia coli-producing extended-spectrum beta-lactamases: importance of community isolates with blaCTX-M genes. Clin Infect Dis (2004) 1.88
Time to blood culture positivity in Staphylococcus aureus bacteremia: association with 30-day mortality. J Infect (2010) 1.84
Surveillance and molecular epidemiology of Klebsiella pneumoniae isolates that produce carbapenemases: first report of OXA-48-like enzymes in North America. Antimicrob Agents Chemother (2012) 1.83
Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains. J Infect Dis (2005) 1.80
Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol (2005) 1.76
Development and validation of a molecular beacon probe-based real-time polymerase chain reaction assay for rapid detection of methicillin resistance in Staphylococcus aureus. Arch Pathol Lab Med (2003) 1.74
Molecular epidemiology over an 11-year period (2000 to 2010) of extended-spectrum β-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol (2011) 1.67
Characteristics of NDM-1-producing Escherichia coli isolates that belong to the successful and virulent clone ST131. Antimicrob Agents Chemother (2011) 1.63
Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary. Emerg Infect Dis (2007) 1.56
Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med (2009) 1.56
Colonization of returning travelers with CTX-M-producing Escherichia coli. J Travel Med (2011) 1.53
Clinical and molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli causing bacteremia in the Rotterdam Area, Netherlands. Antimicrob Agents Chemother (2011) 1.52
High prevalence of ST131 isolates producing CTX-M-15 and CTX-M-14 among extended-spectrum-beta-lactamase-producing Escherichia coli isolates from Canada. Antimicrob Agents Chemother (2010) 1.50
Virulence factors of Escherichia coli isolates that produce CTX-M-type extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2005) 1.49
Molecular methods for pathogen and microbial community detection and characterization: current and potential application in diagnostic microbiology. Infect Genet Evol (2012) 1.48
In vivo selection of fluoroquinolone-resistant Escherichia coli isolates expressing plasmid-mediated quinolone resistance and expanded-spectrum beta-lactamase. Antimicrob Agents Chemother (2006) 1.46
Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother (2005) 1.43
Using a commercial DiversiLab semiautomated repetitive sequence-based PCR typing technique for identification of Escherichia coli clone ST131 producing CTX-M-15. J Clin Microbiol (2009) 1.40
Surveillance for plasmid-mediated quinolone resistance determinants in Enterobacteriaceae within the Calgary Health Region, Canada: the emergence of aac(6')-Ib-cr. J Antimicrob Chemother (2008) 1.38
The characteristics of NDM-producing Klebsiella pneumoniae from Canada. Diagn Microbiol Infect Dis (2011) 1.37
Epidemic Klebsiella pneumoniae ST258 is a hybrid strain. MBio (2014) 1.35
Molecular characteristics of extended-spectrum beta-lactamase-producing Escherichia coli from the Chicago area: high prevalence of ST131 producing CTX-M-15 in community hospitals. Int J Antimicrob Agents (2010) 1.35
Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region: emergence of VIM-2-producing isolates. J Clin Microbiol (2006) 1.31
Molecular epidemiology of extended-spectrum-β-lactamase-producing Klebsiella pneumoniae over a 10 year period in Calgary, Canada. J Antimicrob Chemother (2012) 1.29
Molecular characteristics of travel-related extended-spectrum-beta-lactamase-producing Escherichia coli isolates from the Calgary Health Region. Antimicrob Agents Chemother (2009) 1.26
Incidence and risk factors for acquiring nosocomial urinary tract infection in the critically ill. J Crit Care (2002) 1.24
The latest threat in the war on antimicrobial resistance. Lancet Infect Dis (2010) 1.23
Human case of lobomycosis. Emerg Infect Dis (2004) 1.22
Association between handling of pet treats and infection with Salmonella enterica serotype newport expressing the AmpC beta-lactamase, CMY-2. J Clin Microbiol (2003) 1.20
Population-based assessment of intensive care unit-acquired bloodstream infections in adults: Incidence, risk factors, and associated mortality rate. Crit Care Med (2002) 1.20
Compartmentalization of the gut viral reservoir in HIV-1 infected patients. Retrovirology (2007) 1.19
Effects of routine infant vaccination with the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization with streptococcus pneumoniae in children in Calgary, Canada. Pediatr Infect Dis J (2008) 1.18
The distinct category of healthcare associated bloodstream infections. BMC Infect Dis (2012) 1.15
Progress in the prevention of pneumococcal infection. CMAJ (2005) 1.14
Investigation of sources of potential bias in laboratory surveillance for anti-microbial resistance. Clin Invest Med (2007) 1.14
Global Escherichia coli Sequence Type 131 Clade with blaCTX-M-27 Gene. Emerg Infect Dis (2016) 1.12
Intensive care unit-acquired urinary tract infections in a regional critical care system. Crit Care (2005) 1.11
Development of a novel electronic surveillance system for monitoring of bloodstream infections. Infect Control Hosp Epidemiol (2010) 1.07
Use of beta-lactamase inhibitors in disk tests to detect plasmid-mediated AmpC beta-lactamases. J Clin Microbiol (2004) 1.05
Characteristics of infections caused by extended-spectrum β-lactamase-producing Escherichia coli from community hospitals in South Africa. Diagn Microbiol Infect Dis (2011) 1.03
Community-based outbreaks in vulnerable populations of invasive infections caused by Streptococcus pneumoniae serotypes 5 and 8 in Calgary, Canada. PLoS One (2011) 1.02
Eradication of invasive pneumococcal disease due to the seven-valent pneumococcal conjugate vaccine serotypes in Calgary, Alberta. Pediatr Infect Dis J (2012) 1.01
Travel-related carbapenemase-producing Gram-negative bacteria in Alberta, Canada: the first 3 years. J Clin Microbiol (2014) 1.01
Community-onset disease caused by Citrobacter freundii producing a novel CTX-M beta-lactamase, CTX-M-30, in Canada. Antimicrob Agents Chemother (2004) 0.99
HIV-1 viral diversity and its implications for viral load testing: review of current platforms. Int J Infect Dis (2011) 0.99
The presence of genes encoding for different virulence factors in clonally related Escherichia coli that produce CTX-Ms. Diagn Microbiol Infect Dis (2012) 0.99
Blood cultures in ambulatory outpatients. BMC Infect Dis (2005) 0.98
Gram-negative bacteria that produce carbapenemases causing death attributed to recent foreign hospitalization. Antimicrob Agents Chemother (2013) 0.98
Population-based laboratory surveillance for Giardia sp. and Cryptosporidium sp. infections in a large Canadian health region. BMC Infect Dis (2005) 0.97
Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother (2014) 0.95
The changing burden of pediatric bloodstream infections in Calgary, Canada, 2000-2006. Pediatr Infect Dis J (2009) 0.95
Global incidence of carbapenemase-producing Escherichia coli ST131. Emerg Infect Dis (2014) 0.94
Virulence potential and adherence properties of Escherichia coli that produce CTX-M and NDM β-lactamases. J Med Microbiol (2013) 0.92
Comparison of direct selective versus nonselective agar media plus LIM broth enrichment for determination of group B streptococcus colonization status in pregnant women. Arch Pathol Lab Med (2003) 0.91
Rationale for and protocol of a multi-national population-based bacteremia surveillance collaborative. BMC Res Notes (2009) 0.90
Population-based laboratory surveillance of imported malaria in metropolitan Calgary, 2000-2011. PLoS One (2013) 0.90
Evaluation of beta-lactamase inhibitors in disk tests for detection of plasmid-mediated AmpC beta-lactamases in well-characterized clinical strains of Klebsiella spp. J Clin Microbiol (2005) 0.90
Antibiotic trapping by plasmid-encoded CMY-2 β-lactamase combined with reduced outer membrane permeability as a mechanism of carbapenem resistance in Escherichia coli. Antimicrob Agents Chemother (2013) 0.88
Antimicrobial susceptibility of well-characterised multiresistant CTX-M-producing Escherichia coli: failure of automated systems to detect resistance to piperacillin/tazobactam. Int J Antimicrob Agents (2008) 0.88
Epidemiology of Staphylococcus aureus nasal colonization and influence on outcome in the critically ill. J Crit Care (2009) 0.87
The characteristics of Klebsiella pneumoniae that produce KPC-2 imported from Greece. Diagn Microbiol Infect Dis (2013) 0.87
Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. Retrovirology (2010) 0.85
New and sensitive assay for determining Pseudomonas aeruginosa metallo-beta-lactamase resistance to imipenem. J Clin Microbiol (2008) 0.85
Clinical outcome of empiric antimicrobial therapy of bacteremia due to extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae. BMC Res Notes (2010) 0.85
The laboratory diagnosis of Pseudomonas aeruginosa that produce metallo-β-lactamases in a Dutch tertiary care centre. Scand J Infect Dis (2011) 0.83
Species-level molecular identification of invasive "Streptococcus milleri" group clinical isolates by nucleic acid sequencing in a centralized regional microbiology laboratory. J Clin Microbiol (2005) 0.83
Emerging gram-negative enteric infections. Clin Lab Med (2004) 0.82
Validation of a rapid diagnostic strategy for determination of significant bacterial counts in bronchoalveolar lavage samples. Arch Pathol Lab Med (2005) 0.81
Evaluation of a rapid bacterial ATP assay for screening BAL samples from ICU patients submitted for quantitative bacterial cultures. Diagn Microbiol Infect Dis (2003) 0.80
A case of acute cholecystitis caused by methicillin-resistant Staphylococcus aureus in an immunocompromised patient. Can J Infect Dis Med Microbiol (2011) 0.80
Utility of Gram stain for the microbiological analysis of burn wound surfaces. Arch Pathol Lab Med (2003) 0.79
The characteristics of VIM-1-producing Klebsiella pneumoniae from South Africa. Scand J Infect Dis (2011) 0.78
Gastrointestinal viral load and enteroendocrine cell number are associated with altered survival in HIV-1 infected individuals. PLoS One (2013) 0.77
Human granulocytic anaplasmosis: First reported case in Canada. Can J Infect Dis Med Microbiol (2009) 0.76